HIV Pharmacology: Barriers to the eradication of HIV from the CNS

被引：48

作者：

McGee, Bryan ^{[1
]}

Smith, Nathalie ^{[1
]}

Aweeka, Francesca ^{[1
]}

机构：

[1] Univ Calif San Francisco, Drug Res Unit, San Francisco, CA 94143 USA

来源：

HIV CLINICAL TRIALS | 2006年 / 7卷 / 03期

关键词：

antiretroviral CNS penetration; central nervous system; latent HIV-1;

D O I：

10.1310/AW2H-TP5C-NP43-K6BY

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Total eradication of HIV-1 is not yet achievable, in part because reservoirs of latent HIV-1 can develop within lymphoid tissue, the testes, and the central nervous system (CNS). The presence of HIV-1 in the CNS is clinically significant because of its association with the development of HIV dementia, which occurs in up to one fifth of untreated patients. This review summarizes current theory regarding HIV-1 infection within the CNS, describes physiologic and pharmacologic factors limiting CNS penetration of antiretroviral drugs used to treat HIV-1 infection, and reviews current treatment of CNS HIV-1 infection and HIV encephalopathy.

引用

页码：142 / 153

页数：12

共 80 条

[1] Inflammatory mediators and modulation of blood-brain barrier permeability [J].

Abbott, NJ .

CELLULAR AND MOLECULAR NEUROBIOLOGY, 2000, 20 (02) :131-147

[2] Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients [J].

Antinori, A ;

Giancola, ML ;

Grisetti, S ;

Soldani, F ;

Alba, L ;

Liuzzi, G ;

Amendola, A ;

Capobianchi, M ;

Tozzi, V ;

Perno, CF .

AIDS, 2002, 16 (14) :1867-1876

[3] Tenofovir: A nucleotide analog for the management of human immunodeficiency virus infection [J].

Antoniou, T ;

Park-Wyllie, LY ;

Tseng, AL .

PHARMACOTHERAPY, 2003, 23 (01) :29-43

[4] Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex [J].

Aweeka, F ;

Jayewardene, A ;

Staprans, S ;

Bellibas, SE ;

Kearney, B ;

Lizak, P ;

Novakovic-Agopian, T ;

Price, RW .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1999, 20 (01) :39-43

[5] TEMPORAL TRENDS IN THE INCIDENCE OF HTV-1-RELATED NEUROLOGIC DISEASES - MULTICENTER AIDS COHORT STUDY, 1985-1992 [J].

BACELLAR, H ;

MUNOZ, A ;

MILLER, EN ;

COHEN, BA ;

BESLEY, D ;

SELNES, OA ;

BECKER, JT ;

MCARTHUR, JC .

NEUROLOGY, 1994, 44 (10) :1892-1900

[6] The blood brain barrier in HIV infection [J].

Berger, JR ;

Avison, M .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 :2680-2685

[7] Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV [J].

Capparelli, EV ;

Holland, D ;

Okamoto, C ;

Gragg, B ;

Durelle, J ;

Marquie-Beck, J ;

van den Brande, G ;

Ellis, R ;

Letendre, S .

AIDS, 2005, 19 (09) :949-952

[8] Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid [J].

Capparelli, EV ;

Letendre, SL ;

Ellis, RJ ;

Patel, P ;

Holland, D ;

McCutchan, JA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2504-2506

[9] Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection [J].

Chun, TW ;

Engel, D ;

Berrey, MM ;

Shea, T ;

Corey, L ;

Fauci, AS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) :8869-8873

[10]

Cinque P, 2000, J NEUROVIROL, V6, pS95

← 1 2 3 4 5 6 7 8 →